One-third of older adults with cognitive disorders are taking prescription drugs that could harm them

Adults 65 and older with cognitive disorders such as dementia are more likely to suffer negative effects from drugs that ...
Yahoo Finance

Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region

Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics Market by Disease, by Drug Class, by Distribution Channel, and by Region" report has been added to ResearchAndMarkets ...
RAPS

EMA Highlights Central Nervous System Drug Development Challenges

The European Medicines Agency (EMA) on Tuesday published an analysis highlighting the complexity of developing treatments for central nervous system (CNS) disorders, such as Alzheimer's disease, ...
Medical Daily

Drug Interactions and the Brain: Nervous System Effects and Medication Safety Explained

Six states will require medical proof for Medicaid work exemptions in January, skipping a federal grace year. Who is affected and what to gather. MedPAC Chair Defends $76 Billion Medicare Advantage ...
Nature

Nanoparticle-Mediated Drug Delivery to the Central Nervous System

Nanoparticle-mediated delivery has emerged as a transformative approach to transport therapeutic agents across the blood–brain barrier (BBB) and into the central nervous system (CNS). These systems, ...
Nature

Intra-Arterial Drug Delivery for Central Nervous System Tumors

Intra-arterial drug delivery (IADD) represents a targeted therapeutic approach in which anticancer agents are administered directly into the arteries supplying central nervous system (CNS) tumours. By ...
Healio

FDA advisory committee backs donanemab for early-stage Alzheimer’s

Please provide your email address to receive an email when new articles are posted on . The FDA panel voted 11-0 in favor of donanemab as an effective treatment for early-stage Alzheimer’s. The ...
FierceBiotech

Sanofi inks $400M biobucks deal to test the mettle of Alloy's antisense platform

News of a deal with Alloy Therapeutics arrived about two months after Sanofi made another investment in antisense R&D. (iStock / Getty Images Plus) Sanofi has tapped Alloy Therapeutics to enable ...
Hosted on MSN

Key FDA drugs advisory committee to be reconstituted

The US FDA's Peripheral and Central Nervous System Drugs Advisory Committee has been terminated and will be re-established, according to a notice in the Federal Register. The notice states that the ...
The Hill

FDA panel backs Eli Lilly’s Alzheimer’s drug

A federal advisory panel on Monday voted in favor of recommending Eli Lilly’s new drug that is under consideration for its potential to slow the progression of Alzheimer’s disease. The Food and Drug ...
The Motley Fool

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

Superstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter. The quarter-end position value was $6.84 million, representing a new holding in Axsome Therapeutics ...